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Abstract When the patent of a brand-name, marketed drug
expires, new, generic products are usually offered. Small-
molecule generic and originator drug products are expected
to be chemically identical. Their pharmaceutical similarity
can be typically assessed by simple regulatory criteria such
as the expectation that the 90 % confidence interval for the
ratio of geometric means of some pharmacokinetic param-
eters be between 0.80 and 1.25. When such criteria are sat-
isfied, the drug products are generally considered to exhibit
therapeutic equivalence. They are then usually interchanged
freely within individual patients. Biological drugs are com-
plex proteins, for instance, because of their large size, intri-
cate structure, sensitivity to environmental conditions,
difficult manufacturing procedures, and the possibility of
immunogenicity. Generic and brand-name biologic products
can be expected to show only similarity but not identity in
their various features and clinical effects. Consequently, the
determination of biosimilarity is also a complicated process
which involves assessment of the totality of the evidence for
the close similarity of the two products. Moreover, even
when biosimilarity has been established, it may not be
assumed that the two biosimilar products can be automati-
cally substituted by pharmacists. This generally requires
additional, careful considerations. Without declaring inter-
changeability, a new product could be prescribed, i.e. it is
prescribable. However, two products can be automatically
substituted only if they are interchangeable. Interchange-
ability is a statistical term and it means that products can be
used in any order in the same patient without considering the
treatment history. The concepts of interchangeability and
prescribability have been widely discussed in the past but
only in relation to small molecule generics. In this paper we
apply these concepts to biosimilars and we discuss: defini-
tions of prescribability and interchangeability and their sta-
tistical implementation; the relation between bioequivalence
and interchangeability for small-molecule drug products;
regulatory requirements and expectations of biosimilar
products in various jurisdictions; possible statistical
approaches to establish the similarity and interchangeability
of biologic drug products; definition of other technical terms
such as switchability and automatic substitution. The paper
will be concluded with a discussion of the anticipated future
use of interchangeability of biological drug products.
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Introduction
New drug development is a lengthy, expensive, and com-
plex process. The high and increasing cost of the devel-
opment is reflected in the increasing price which is a
constant source of concern for governments, health care
providers and generally for the public [1]. However, when
the patents protecting a drug product expire, then com-
petitor products can appear on the market. A competitor’s
drug products are called generics. Generics contain the
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same active ingredient in the same amount as the originator
formulation but at a lower price [2].
It is a fundamental principle in clinical pharmacology
that the therapeutic effect is solely determined by the
plasma concentration of the active molecule. Conse-
quently, regardless of the formulation factors, if the plasma
concentrations of two products are the same or very similar
then the therapeutic effects also must be practically the
same. This is the basic concept for the regulatory approval
of generic products.
Biological drugs are not synthesized chemically but are
made by living organisms. They are much larger than
small-molecule drugs and have much more complicated,
primary, secondary, tertiary and quaternary structures.
They may exhibit immunogenicity (unwanted immune
response) when the immune system recognizes a large
molecule as a foreign invader. Their manufacturing pro-
cedures are difficult and sensitive to environmental con-
ditions such as temperature, light and pressure.
Consequently, a ‘‘generic’’ biological product cannot be
identical but only similar (‘‘biosimilar’’) to the drug of an
originator. The two products should be highly similar so
that their clinical effects should also be very close. The
issue of what is ‘‘highly similar’’ is a matter of judgment
and is based on the totality of all the evidence. This
involves several considerations including structural, func-
tional, analytical, immunological, pharmacokinetic, phar-
macodynamic, manufacturing and clinical similarities.
Even if two products are judged and declared to be bio-
similar, they may not be readily substituted automatically
within individuals from one to the other by pharmacists. This
kind of interchangeability requires much more convincing
evidence, which can be obtained only from additional
investigations and calls from further, careful judgment.
This article discusses statistical and regulatory aspects
of the interchangeability of biologicals. First, definitions of
interchangeability and conditions for its application will be
presented. This will be followed by past experience for the
evaluation of bioequivalence and interchangeability for
small-molecule drug products. Regulatory requirements
and expectations for biosimilar products in various juris-
dictions will then be discussed. Thereafter, statistical
approaches to demonstrate the similarity and interchange-
ability of biological drug products will be summarized.
Finally, the prospective future use of the interchangeability
of biologics will be contemplated.
The first part of this paper summarizes the developments
in this field in the last 20 years. The statistical aspects of
bioequivalence are a constantly evolving area. There are
many facets of this problem, but in this communication we
discuss only the statistical and regulatory aspects. Finally,
we shall summarize how these statistical principles are
reflected in the legislation in different jurisdictions.
Average bioequivalence for the approval of generic
products
Bioequivalence studies are required for granting marketing
authorization for generic medicinal products. The exact
requirements slightly differ between main jurisdictions
such as the US, EU, and Japan, but the general approach is
the same.
The approval is based on the results of a bioequivalence
study. The plasma concentrations of the generic (called test
product, T) and the originator (reference, R) formulations
are compared in a limited number (somewhere between 18
and 60) healthy volunteers in a crossover fashion. Half of
the volunteers are randomly assigned to get the test drug
and after it is eliminated from the body, they receive the
reference product. For the other half of the group the order
is reversed, receiving first the reference and then the test
product. After drug ingestion, several blood samples are
obtained and the concentrations of the active substance are
determined.
To demonstrate bioequivalence, it should be shown that
derived parameters from the concentrations, like the areas
under the curve (AUC) of the test and reference products,
are not really different, they are similar to each other.
The currently used method to assess bioequivalence was
proposed by the FDA’s statistician Schuirmann [3] and is
called the ‘‘two one-sided tests’’ (TOST) method. In the
first step, the logarithms of the relevant pharmacokinetic
parameters are taken. In a second step, after the eliminating
period and sequence effects, differences between individ-
ual values are calculated. We denote the mean of individual
differences by mT-mR.
In the third step, two one-sided t-tests are performed:
Test 1 mT  mR\  H ð1Þ
Test 2 mT  mR [ H ð2Þ
If both tests are rejected at the 0.05 level, then we have
established, with 90 % confidence, that the mean of the
individual logarithmic differences is between -H and H.
H is a regulatory cutoff, usually log (1.25). It is common
that the TOST result is interpreted after back-transforma-
tion, that is, after taking the antilogarithms of Eqs. 1 and 2.
If both equations are rejected then it can be stated, with
90 % confidence, that the geometric mean of the individual
ratios is between 0.80 and 1.25. If this holds, then a generic
product is approvable at least from the bioequivalence
viewpoint.
The TOST procedure assesses if the difference
between the (logarithmic) averages satisfies the regula-
tory criterion for bioequivalence (Eqs. 1, 2). Therefore, it
is a test for determination of average bioequivalence
(ABE).
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Critique of the average bioequivalence concept
Testing bioequivalence in the way presented above has
become the general, standard procedure. However, it can
be subject to questions and criticisms. There are at least
three issues:
• First, ABE focuses only on the differences between the
mean values and neglects the possible differences
between the variances. It is possible that due to
technological problems one of the products will not
have constant quality, and due to the fluctuations in
critical technological parameters, a patient sometimes
will be overdosed and sometimes will be underdosed.
Quality differences between two drug products could
be measured by comparing the between- and within-
subject differences, but the current ABE decision
criterion is independent of this parameter.
• The second problem is what is called subject-by-
formulation interaction. In theory it is possible that
there are subjects who have the highest value with the
test formulation but have the lowest value with the
reference product. Also, vice versa, other subjects with
the lowest value with the reference formulation can
have the highest value with the test product. The means
and even the variations of test and reference formula-
tions could be the same, nevertheless, individuals
would exhibit differing effects after receiving the two
drug products.
• The third issue is related to the fact that the maximum
allowed difference between the means, (the regulatory
cutoff) is fixed, regardless of the between- or within-
subject variances. It could be argued that, if a drug has
a narrow therapeutic window, the applied regulatory
cutoff allows too wide difference between the means of
the products. In other cases, the regulatory cutoff is too
strict if, for biological reasons, the drug concentration
in the plasma fluctuates very widely. For such drugs,
called highly variable drugs, bioequivalence can be
demonstrated only if an unreasonably high number of
volunteers, a hundred or even more, participate in the
bioequivalence study. The associated development
costs could be a deterring factor for most generic
developers and would wipe out the economic advantage
of the generic alternative.
Prescribability and interchangeability
Anderson and Hauck recognized [4] the deficiencies of the
standard method (Eqs. 1, 2) for assessing bioequivalence.
In their original publication [4] Anderson and Hauck
focused only on generic drugs, as in 1990 the term
‘biosimilarity’ and the category of biosimilar drugs as a
whole was unknown.
To start with, they distinguished between two conditions
in which a patient could encounter a generic product. The
first scenario is that the patient had no prior exposure to a
drug in any of its forms, i.e. if s/he is naı¨ve to the drug. In
such situations, any of the approved products are prescrib-
able provided that their safety and efficacy are satisfactory
and, therefore, they have been approved by regulators.
However, after the patient has started to receive one of the
products, it may not be substituted by another formulation.
The second scenario is when the patient is already tak-
ing the drug but opts for a cheaper alternative for economic
reasons. In this scenario the different products must be
therapeutically equivalent. Therefore, the products must be
switchable within individuals. The switch usually occurs
from the reference product to the test preparation (R ? T)
but alternative directions are also possible like the T ? R
and T ? T0 switch; here T0 is a second generic, test
product. The products R, T and T0 must be interchangeable
in any possible sense to achieve the same therapeutic effect
after a switch.
Depending on the condition, two test models were
proposed. To describe prescribability quantitatively the so-
called population bioequivalence (PBE) model was devel-
oped. This required comparison of the population distri-
butions of the relevant pharmacokinetic parameters. A
simple parallel-group design study was considered ade-
quate to establish PBE.
In contrast, interchangeability could be demonstrated by
satisfying the requirements of a model for individual bio-
equivalence (IBE). Essentially, IBE is an extended version of
ABE and it eliminates the shortcomings of ABE by adding
new terms to the statistical decision rule. But the implemen-
tation of IBE calls for a more complex study design: IBE
requires investigations with a crossover design in which both
drug products are measured (at least) twice within individuals.
Individual BE and interchangeability for small-molecule
drug products were widely discussed for about a decade,
starting in the early 1990s. However, the need for more
complicated studies, three or even more than three period
crossover studies was questioned. The draft guideline
released by the FDA [5] met serious criticism and was later
superseded by another guideline [6] in which the FDA
reverted back to ABE. The concept of IBE was acknowl-
edged but was never accepted by the CHMP, the European
regulatory body.
Biosimilars, switchability and interchangeability
A statement of interchangeability between a generic bio-
logic and a reference product is distinct from assessments
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of their biosimilarity. Considerations in various jurisdic-
tions will be discussed below.
United States
The Biologics Price Competition and Innovation (BPCI)
Act of 2009 in the US, clearly defines, separately, both
biosimilarity and interchangeability [7].
The BPCI Act defines the term biosimilar (or biosimi-
larity) as when the biological product is highly similar to
the reference product (notwithstanding minor differences
in clinically inactive components), and also when there are
no clinically meaningful differences between the biological
product and the reference product in terms of safety, purity
and potency.
The BPCI Act of the US provides explicit definitions
and conditions for interchangeability. ‘‘The terms inter-
changeable and interchangeability mean that: (1) the bio-
logical product is biosimilar to the reference product; (2)
the biological product can be expected to produce the same
clinical result as the reference product in any given patient;
(3) for a product administered more than once, the risks of
safety and reduced efficacy of alternating and switching are
not greater than with the use of the reference product
without alternating or switching.’’ (Emphasis has been
added).
There is a clear and strong distinction between biosim-
ilarity and interchangeability. Biosimilarity is a precondi-
tion of interchangeability. The regulatory approval of the
biosimilarity of two products does not imply at all their
interchangeability. If two biologic products have already
been approved and are marketed, an additional application
must be submitted which would demonstrate that condi-
tions for their interchangeability are also satisfied.
The strong distinction and hierarchy between the bio-
similarity and interchangeability of biologic products is in
sharp contrast to the close parallel between the bioequiv-
alence and interchangeability of small-molecule drug
products.
However, while the BPCI Act distinguished between
biosimilarity and interchangeability, such a distinction is
still to be seen in the corresponding FDA guidelines. This
has led to legal controversies.
Automatic substitution in the United States
The BPCI Act of the US also decrees important conse-
quences of the approval of interchangeability between
biologic drug products. The BPCI Act states that the
interchangeable ‘‘biological product may be substituted for
the reference product without the intervention of the health
care provider who prescribed the reference product’’ [7].
Consequently, according to the BPCI Act, if a test product
is judged to be interchangeable with the reference product
then it may be substituted, even alternated, without a
possible intervention, or even notification, of the pre-
scribing physician.
This is a very permissive stipulation and has raised
concerns at the level of state legislations. The basis of these
concerns is that substitution of a drug product by another
could give rise to changes of the safety and efficacy in
individuals. It is expected, however, that risks associated
with these changes are well controlled.
For instance, when a patient is switched from a refer-
ence formulation to a test product, R ? T, then the asso-
ciated risk should not be higher than when the subject is
exposed to the reference product twice: R ? R0. This was
the sense of earlier considerations of individual BE. Sce-
narios of switching and alternating have not been consid-
ered by the FDA. On the other hand, until end of 2013, ten
states introduced measures which permitted the substitu-
tion of biological products. Thereby, they contravened the
federal BPCI Act which had required a separate, additional
designation of interchangeability. The decrees of the states
also prohibited automatic substitution by pharmacists. Four
others approved such measures, though three put sunset
clauses on the notification requirement, meaning the
restriction will die after a certain number of years [8].
Thus it seems that a regulation which does not answer
possible concerns may achieve an outcome which could be
opposite from its intended purpose. Biologics are compli-
cated drugs and their clinical responses are usually also
complicated and sensitive to various conditions. Conse-
quently, prescribing physicians may want to monitor the
responses following the switching of drug products. If the
consequence of approved interchangeability were free,
relaxed substitution, then physicians, and patients, may
prefer not to use the option of interchangeability. But the
legal situation is in constant flux. For example, on 12
October 2013, California Governor Jerry Brown vetoed
legislation known as SB 598, the legislation which would
have forbidden a pharmacist from substituting a biosimilar
for a brand-name biological if a physician ticked a ‘do not
substitute’ box [9].
Canada
In Canada, the term ‘‘substitutability’’ is applied to two
products which can both be used in lieu of the other during
and within the same treatment period, i.e. for inter-
changeability as discussed in this paper. The position of
Health Canada on the substitution of biological products
(biosimilars are called ‘‘subsequent-entry’’ products in
Canada) is clear but rather soft: ‘‘Health Canada does not
support the automatic substitution of a subsequent-entry
biologic for its reference biologic drug. Health Canada
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therefore recommends that physicians make only well-
informed decisions regarding therapeutic interchange’’
[10]. The position of Health Canada does not have legal
authority. Funds for the reimbursement of pharmaceutical
expenses are dispensed by the provinces. They will be keen
to promote introduction of new generic biologic products,
i.e. their prescribability. The interchangeability of biologic
products, and the related conditions, will be diverse and
controversial.
European Union
The EU was the first region in the world to have set up
legal frameworks and regulatory pathways for biosimilars.
In fact, the word ‘‘biosimilars’’ was coined during this
legislative process, and legal terms for ‘‘similar biologi-
cals’’ are different in other jurisdictions. They are called
follow-on biologics (FOB) in the US, subsequent-entry
biologics (SEB) in Canada, and follow-on proteins (FOP)
in Japan. In this paper we use biosimilars as shorthand for
similar biologicals regardless of geographical implications,
because the concepts behind these names are the same
though local variations exist. The concept of a ‘‘similar
biological medicinal product’’ was adopted in EU phar-
maceutical legislation in 2004 and came into effect in
2005. The European Medicines Agency (EMA) was the
first to lay down an abbreviated regulatory pathway for
biosimilars. As of December 2013, 17 biosimilars within
the product classes of human growth hormone, granulocyte
colony-stimulating factor and erythropoietin TNF-alpha
have been approved in Europe [11]. Only the EMA can
grant marketing authorization for biosimilars in the Euro-
pean Union. More precisely, the European Commission
issues the decisions concerning the authorization of these
medicinal products on the basis of the scientific opinions
from the EMA. The resulting marketing authorization is
valid in all EU Member States.
For granting approval for a biosimilar product, EMA
requires clinical trials, including comparability studies to
the originator product, to demonstrate safety and efficacy.
Unlike generics, demonstration of bioequivalence is not
enough for biosimilars. Additionally, the prospective
market authorization holder also must demonstrate lack or
at least comparable immunogenicity in long-term clinical
trials. Guidelines were established to provide further details
on specific needs for demonstrating biosimilarity for four
primary product classes.
The EMA has made it clear that a biosimilar is not the
same as a generic drug, and has handed the interchange-
ability issue over to individual countries. As an EMA
document states [12]: ‘‘The EMA evaluates biosimilar
medicines for authorization purposes. The Agency’s eval-
uations do not include recommendations on whether a
biosimilar should be used interchangeably with its refer-
ence medicine. For questions related to switching from one
biological medicine to another, patients should speak to
their doctor or pharmacist.’’ Some countries went further
and legislation has been passed which prohibits automatic
substitution by pharmacists [13]. Given that most currently
approved biosimilars are applicable only in hospital set-
tings, the impact of such a strict prohibition is moderate.
Much more important is the reimbursement policy [14]
where there are many national variations. One of the
options is that new patients need to be treated with a bio-
similar product if it is available, otherwise the treatment is
not reimbursed. However, patients who have already been
treated with a brand-name biological will continue
receiving the same biological brand. Consequently, such a
policy allows prescribability but not the interchangeability
of biosimilar products. To describe these different scenar-
ios, a European Consensus Group on Biosimilars proposed
to make distinctions between interchangeability, switching
and substitution. According to the consensus document
[15]:
• Interchangeability means changing one medicine with
the agreement of the prescriber.
• Switching means a decision by the treating physician to
exchange one medicine for another.
• Substitution means of the practice of dispensing one
medicine instead of another equivalent and inter-
changeable medicine at the pharmacy level without
consulting the prescriber.
Making such distinctions between the post-approval use
of biosimilars might be needed to describe the different
possibilities. But reloading the meaning of these common
English words which so far have been used as synonyms,
or with different meaning in the scientific literature, could
lead to confusion. The word switching appears to be a
particularly bad choice of wording because native English
speakers seem to associate switching with the inadvertent
exchange of medicines.
Statistical considerations on the interchangeability
of biological products
The definitions of the American BPCI Act for the inter-
changeability of biologicals were outlined earlier. One of
them is particularly forbidding, apparently categorical:
‘‘the biological product can be expected to produce the
same clinical result as the reference product in any given
patient’’. Responses of patients are variable and the same
clinical response may not be anticipated. Furthermore, the
expectation of the same result in any given patient could be
interpreted to mean that if an individual experiences an
unexpected (not to say, not the ‘‘same’’) therapeutic or
Statistical and regulatory considerations S9
123
adverse effect s/he may well seek recourse. Lawyers,
notably in the US, would undoubtedly encourage this.
However, the word ‘‘expected’’ in the above phrase
could be interpreted that the ‘‘same clinical result in any
given patient’’ is not a categorical rule but only an
expectation. ‘‘Expectation’’ also has a probabilistic mean-
ing which involves some stated statistical assurance. It is
hoped that this interpretation will be duly considered and
adopted.
While many biologicals have long terminal half-lives,
some don’t. With these, it is possible to contemplate
crossover investigations which would enable the assess-
ment of features of interchangeability. Notably, switching
between two biological products, either reference (R) or
test (T), such as R ? T, T ? R, R ? R0, T ? T0, could
be investigated by Balaam’s 4 9 2 crossover design with 4
sequences and 2 periods [16, 19], including RT, TR, RR0,
TT0. Here, e.g., RT refers to a sequence in which first the
reference and then, after a sufficient washout period, the
test product is provided to each individual. R and R0 denote
two administrations of the reference product. Similarly,
alternating between the test and reference products, i.e.
R ? T?R0, T ? R?T0, could be studied by a
2-sequence, 3-period design with the sequences of RTR0,
TRT0. Finally, both switching and alternating could be
investigated by modifying Balaam’s design in four
sequences and either two or three periods: TT0, RR0, TRT0,
RTR0.
Little work has been undertaken so far on statistical
procedures for the assessment of interchangeability of
biologicals. Chow et al. [17] developed switching and
alternating indices. These were based on the concept of a
biosimilarity index which had been defined earlier [18].
This evaluates whether the probability of concluding
average biosimilarity (corresponding to ABE) in a contrast
of the biosimilar test and the reference products (T vs R) is
similar to the ‘‘reproducibility’’ probability obtained in a
comparison of two applications of the reference product (R
vs R). The switching and alternating indices extend this
concept to the more complicated designs outlined above.
Statistical approaches for evaluating the interchange-
ability of biological products will be undoubtedly devel-
oped further in the near future. They will provide a useful
tool for the regulatory assessment of the evidence.
Conclusions
The approach to the interchangeability of drug products is
very different for small-molecule drugs compared with
biologicals. With small-molecule drugs, approval auto-
matically indicates, in most cases, interchangeability.
Generic competition is based on that principle, though this
fact is rarely recognized. In contrast, regulatory approvals
of biosimilar products neither implicate nor prohibit
interchangeability. Drug regulatory authorities are very
cautious to make any statement in this regard.
In the US, the BPCI Act theoretically allows, but places
very strong limitations on, substitutions of biologics. More
importantly, the practical details of how to demonstrate
interchangeability are lacking. Theoretically, the individual
BE concept could serve as a theoretical framework to
assess interchangeability, but there are other proposals
[19]. None of them have been accepted yet by US regu-
lators, but strong differences in the interpretation of bio-
similarity requirements between legislations at the federal
and state level have led to a resurgence of interest in
defining precise, statistically testable criteria of prescrib-
ability and interchangeability.
In the EU, the procedures of approving a biosimilar and
making a statement about its interchangeability are clearly
separated. The first is a centralized procedure, i.e. the
decision is made at the Community level. The approvals
are based on clearly laid-out regulatory requirements [20].
In contrast, to make statements about interchangeability is
delegated to the national level. In the 28 member states,
different usage patterns have emerged such as substitution
in special cases, switching, or restricting the use of bio-
similars only to previously untreated patients. The scien-
tific background behind these policies is unclear but setting
clear criteria for interchangeability and prescribability are
not planned in any of the member states or at the EU level.
It is questionable that the situation will ever change
because such a discussion would demand a coordinated and
comprehensive approach from the EMA and from the
competent national authorities. Without clear regulatory
criteria, biosimilar producers will not consider sponsoring
studies with the goal of demonstrating the interchange-
ability of their products.
Indeed, there are some initial results and clinical studies
that have been actually performed, especially in Europe,
between brand-name biologicals and biosimilar products.
Such studies have been conducted on products that had
been approved by the EMA, including those of granulocyte
colony stimulating factors (filgrastim), human recombinant
growth hormones (somatotropin) and erythropoietins
(epoetin-alfa and epoetin-zeta) [21]. Notably, the switching
of erythropoietin products was investigated in several
crossover clinical trials [22, 23]. Reviews of these studies
could not identify safety risks associated with switching
between the biopharmaceutical products [21, 24].
Restricting interchangeability limits the competition which
has direct economic consequences. It is acknowledged that
interchangeability could be an elusive goal in many cases.
This goal is not so elusive when the molecular weight is
relatively small and the antibody formation risk is
S10 L. To´thfalusi et al.
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negligible. Hopefully, experience will be gained in time
also with comparative studies of biological products. This
could lead to formalized regulatory conditions to establish
the interchangeability of biological products.
Conflict of interest The authors declare no conflict of interest.
References
1. Ess, S.M., Schneeweiss, S., Szucs, T.D.: European healthcare
policies for controlling drug expenditure. Pharmacoeconomics
21(2), 89–103 (2003)
2. Dalen, D.M., Strom, S., Haabeth, T.: Price regulation and generic
competition in the pharmaceutical market. Eur. J. Health Econ.
7(3), 208–214 (2006)
3. Schuirmann, D.J.: A comparison of the two one-sided tests pro-
cedure and the power approach for assessing the equivalence of
average bioavailability. J. Pharmacokinet. Biopharm. 15(6),
657–680 (1987)
4. Anderson, S., Hauck, W.W.: Consideration of individual bio-
equivalence. J. Pharmacokinet. Biopharm. 18(3), 259–273 (1990)
5. FDA: Guidance on statistical approaches to establishing bio-
equivalence. Center for Drug Evaluation and Research, U.S. Food
and Drug Administration (2001)
6. FDA: Guidance on bioavailability and bioequivalence studies for
orally administered drug products—general consideration. Center
for Drug Evaluation and Research, U.S. Food and Drug Admin-
istration, Rockville (2003)
7. BPCI Act. Biologics Price Competition and Innovation Act of
2009. Federal Register. 2010; H.R. 3590-686-702. http://www.
fda.gov/downloads/Drugs/GuidanceComplianceRegulatory%
20Information/UCM216146.pdf. Accessed 15 Jan 2014
8. GaBI online: US state legislation on biosimilars substitution.
GaBI J. 2(3), 155–156 (2013)
9. GaBI online: California governor vetoes biosimilars bill. http://
www.gabionline.net/Policies-Legislation/California-governor-
vetoes-biosimilars-bill (2013). Accessed 15 Jan 2014
10. Health Canada: Questions and answers to accompany the final
Guidance for Sponsors: information and submission requirements
for subsequent entry biologics (SEBs). Question 15. Ottawa, ON,
2010. http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-
demande/guides/seb-pbu/notice-avis_seb-pbu_2010-eng.php.
Accessed 15 Jan 2014
11. GaBI Online: Biosimilars approved in Europe (Last update: 22
November 2013) http://gabionline.net/Biosimilars/General/Biosi
milars-approved-in-Europe. Accessed 15 Jan 20112
12. EMA: Questions and answers on biosimilar medicines (similar
biological medicinal products). London, United Kingdom http://
www.ema.europa.eu/docs/en_GB/document_library/Medicine_
QA/2009/12/WC500020062.pdf. Accessed 05 Jan 2014
13. Biocentury: French parliament OKs biosimilar substitution http://
www.biocentury.com/dailynews/politics/2013-12-12/french-par
liament-oks-biosimilar-substitution (2013). Accessed 05 Jan 2014
14. Declerck, P.J., Simoens, S.: European perspective on the market
accessibility of biosimilars. Biosimilars 2, 33–40 (2012)
15. Steering Group On Access To Medicines In Europe: What you
need to know about biosimilar medicinal products. Directorate
General for Enterprise and Industry of the European Commission.
http://ec.europa.eu/enterprise/sectors/healthcare/competitiveness/
process_on_corporate_responsibility/platform_access/index_en.
htm#h2-6 (2013). Accessed 03 Jan 2014
16. Lu, Y., Chow, S.C., Zhang, Z.Z.: Statistical designs for assessing
interchangeability of biosimilar products. Drug Designing 2(3),
2–6 (2013)
17. Chow, S.C., Yang, L.Y., Starr, A., Chiu, S.T.: Statistical methods
for assessing interchangeability of biosimilars. Stat. Med. 32(3),
442–448 (2013)
18. Hsieh, T.C., Chow, S.C., Yang, L.Y., Chi, E.: The evaluation of
biosimilarity index based on reproducibility probability for
assessing followon biologics. Stat. Med. 32(3), 406–414 (2013)
19. Endrenyi, L., Chang, C., Chow, S.C., Tothfalusi, L.: On the
interchangeability of biologic drug products. Stat. Med. 32(3),
434–441 (2013)
20. EMA: Guideline on Similar Medicinal Biological Products.
Committee for Medicinal Products for Human Use, London,
United Kingdom. http://www.ema.europa.eu/docs/en_GB/docu
ment_library/Scientific_guideline/2009/09/WC500003517.pdf
(2005). Accessed 26 June 2013
21. Ebbers, H.C., Muenzberg, M., Schellekens, H.: The safety of
switching between therapeutic proteins. Expert Opin. Biol. Ther.
12(11), 1473–1485 (2012)
22. Wizemann, V., Rutkowski, B., Baldamus, C., Epoetin Zeta Study
Group: Comparison of the therapeutic effects of epoetin zeta to
epoetin alfa in the maintenance phase of renal anaemia treatment.
Curr. Med. Res. Opin. 24(3), 625–637 (2008)
23. Cho, S.H., Lim, H.S., Ghim, J.L., et al.: Pharmacokinetics, tol-
erability, a bioequivalence comparison of three different intra-
venous formulations of recombinant human erythropoietin in
healthy Korean adult male volunteers: an open-label, random-
ized-sequence, three-treatment, three-way crossover study. Clin.
Ther. 31(5), 1046–1053 (2009)
24. Ebbers, H.C., Crow, S.A., Yulto, A.C., Schellekens, H.: Inter-
changeability, immunogenicity and biosimilars. Nat. Biotechnol.
30(12), 1186–1190 (2012)
Statistical and regulatory considerations S11
123
